Get started
Arcus Biosciences, Inc.Arcus Biosciences, Inc.Arcus Biosciences, Inc.

Arcus Biosciences, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

RCUS chart


Full chart

RCUS upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.46 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−3.15 USD
Net income (FY)
‪−307.00 M‬ USD
Revenue (FY)
‪117.00 M‬ USD
Shares float
‪49.26 M‬
Beta (1Y)
2.32

Employees


Employees (FY)
577
Change (1Y)
+77 +15.40%
Revenue / Employee (1Y)
‪202.77 K‬ USD
Net income / Employee (1Y)
‪−532.06 K‬ USD

About Arcus Biosciences, Inc.


Sector
Health Technology
Industry
Biotechnology
CEO
Terry J. Rosen
Website
arcusbio.com
Headquarters
Hayward
Founded
2015
FIGI
BBG00DQD26W3
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

RCUS news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of RCUS is 15.91 USD — it has decreased by −0.31% in the past 24 hours. Watch Arcus Biosciences, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Arcus Biosciences, Inc. stocks are traded under the ticker RCUS.
RCUS stock has fallen by −2.15% compared to the previous week, the month change is a 11.34% rise, over the last year Arcus Biosciences, Inc. has showed a −10.67% decrease.
We've gathered analysts' opinions on Arcus Biosciences, Inc. future price: according to them, RCUS price has a max estimate of 46.00 USD and a min estimate of 20.00 USD. Watch RCUS chart and read a more detailed Arcus Biosciences, Inc. stock forecast: see what analysts think of Arcus Biosciences, Inc. and suggest that you do with its stocks.
RCUS reached its all-time high on Nov 22, 2021 with the price of 49.10 USD, and its all-time low was 6.30 USD and was reached on Aug 5, 2019. View more price dynamics on RCUS chart.
See other stocks reaching their highest and lowest prices.
RCUS stock is 3.49% volatile and has beta coefficient of 2.32. Track Arcus Biosciences, Inc. stock price on the chart and check out the list of the most volatile stocks — is Arcus Biosciences, Inc. there?
Today Arcus Biosciences, Inc. has the market capitalization of ‪1.46 B‬, it has decreased by −0.75% over the last week.
Yes, you can track Arcus Biosciences, Inc. financials in yearly and quarterly reports right on TradingView.
Arcus Biosciences, Inc. is going to release the next earnings report on Feb 19, 2025. Keep track of upcoming events with our Earnings Calendar.
RCUS earnings for the last quarter are −1.00 USD per share, whereas the estimation was −1.06 USD resulting in a 5.33% surprise. The estimated earnings for the next quarter are −1.25 USD per share. See more details about Arcus Biosciences, Inc. earnings.
Arcus Biosciences, Inc. revenue for the last quarter amounts to ‪48.00 M‬ USD, despite the estimated figure of ‪38.95 M‬ USD. In the next quarter, revenue is expected to reach ‪29.33 M‬ USD.
RCUS net income for the last quarter is ‪−92.00 M‬ USD, while the quarter before that showed ‪−93.00 M‬ USD of net income which accounts for 1.08% change. Track more Arcus Biosciences, Inc. financial stats to get the full picture.
No, RCUS doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 25, 2024, the company has 577.00 employees. See our rating of the largest employees — is Arcus Biosciences, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Arcus Biosciences, Inc. EBITDA is ‪−286.00 M‬ USD, and current EBITDA margin is −276.92%. See more stats in Arcus Biosciences, Inc. financial statements.
Like other stocks, RCUS shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Arcus Biosciences, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Arcus Biosciences, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Arcus Biosciences, Inc. stock shows the sell signal. See more of Arcus Biosciences, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.